Pasar al contenido principal

A Phase 3, randomised, double-blind, parallel-group, event driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight related complications or risk factors for CVD

Abierta
  • Código protocolo: 1404-0040
  • Código EudraCT: No aplica
  • Grupo de investigación: Diabetes y Metabolismo
  • Servicio: Endocrinología
  • Investigador/a principal:  Simó Canonge, Rafael
  • Patología: Malalties endocrines, nutricionals i metabòliques
  • Fase: Fase III
  • Estado: Reclutando voluntarios